Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other financing activities (2016 - 2019)

Northwest Biotherapeutics' Other financing activities history spans 8 years, with the latest figure at $108000.0 for Q4 2019.

  • Quarterly results put Other financing activities at $108000.0 for Q4 2019, changed N/A from a year ago — trailing twelve months through Dec 2019 was $108000.0 (down 21.74% YoY), and the annual figure for FY2019 was $108000.0, down 21.74%.
  • Other financing activities for Q4 2019 was $108000.0 at Northwest Biotherapeutics, down from $138000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $2.6 million in Q3 2017 to a low of -$2.6 million in Q4 2017.
  • The 4-year median for Other financing activities is $321000.0 (2016), against an average of $182666.7.
  • Peak annual rise in Other financing activities hit 694.39% in 2017, while the deepest fall reached 894.39% in 2017.
  • Year by year, Other financing activities stood at $321000.0 in 2016, then tumbled by 894.39% to -$2.6 million in 2017, then soared by 105.41% to $138000.0 in 2018, then dropped by 21.74% to $108000.0 in 2019.
  • According to Business Quant data, Other financing activities over the past three periods came in at $108000.0, $138000.0, and -$2.6 million for Q4 2019, Q2 2018, and Q4 2017 respectively.